Medroxin Dosage/Direction for Use

Prevention of Pregnancy: Both the 1 mL vial and the 1 mL prefilled syringe of Medroxyprogesterone Acetate should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.
The recommended dose is 150 mg of Medroxyprogesterone Acetate every 3 months (13 weeks) administered by deep IM injection in the gluteal or deltoid muscle. Medroxyprogesterone Acetate should not be used as a long-term birth control method (i.e. longer than 2 years) unless other birth control methods are considered inadequate.
To ensure the patient is not pregnant at the time of the first injection, the first injection should be given ONLY during the first 5 days of a normal menstrual period; ONLY within the first 5-days postpartum if not breast-feeding; and if exclusively breast-feeding, ONLY at the sixth postpartum week. If the time interval between injections is greater than 13 weeks, the physician should determine that the patient is not pregnant before administering the drug. The efficacy of Medroxyprogesterone Acetate depends on adherence to the dosage schedule of administration.
Switching from other Methods of Contraception: When switching from other contraceptive methods, Medroxyprogesterone Acetate should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods, (e.g., patients switching from oral contraceptives should have their first injection of Medroxyprogesterone Acetate on the day after the last active tablet or at the latest, on the day following the final inactive tablet).